Navigation Links
Micell Technologies Presents Data on Novel Drug-Eluting Stents

number of issues including inherently thrombogenic polymers, residual drugs and patient compliance issues related to the necessary oral anti-platelet therapy such as Plavix and aspirin, required of patients who receive drug-eluting stents.

"Our technology provides an opportunity for optimal design of therapeutic profiles using both anti-restenosis and anti-thrombotic compounds to address both short and long-term safety of drug-eluting stents," said James B. McClain, founder and Chief Technology Officer of Micell Technologies. "This approach which includes multi-drug formulations in biodegradable polymers has the potential to provide improved benefits for both patients and clinicians."

Micell Technologies' novel approach to surface modification of medical devices provides an opportunity to deliver the next generation of drug-eluting stents by maintaining morphology of therapeutic compounds and providing manufacturing processes that apply discrete and independent therapies within a single, multi-therapy coating.

About Micell

Micell Technologies is a privately-held, early-stage biomedical company dedicated to applying its unique surface and polymer modification technologies for improved patient benefits and accelerated product development for medical device and drug delivery applications. The Company's patented processes and methods for medical device surface modification using supercritical fluids are focused on improvements to current polymer based drug-eluting technologies. To learn more, please visit our website at www.micell.com

Contact: James McClain Ph.D., Chief Technology Officer

Micell Technologies: (919) 313-2111

CONTACT: James McClain Ph.D., Chief Technology Officer of MicellTechnologies, +1-919-313-2111

Web site: http://www.micell.com/

Terms and conditions of use apply

'"/>




Page: 1 2 3

Related medicine technology :

1. Neose Technologies to Present at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
2. New Report Looking at Chiral Technologies Analyzes the Global Market Growth Forecasts Driven By Two Very Important Components as Single Isomer Drugs and Single Enantiomer Pharmaceuticals
3. Palatin Technologies and King Pharmaceuticals Report Data Showing Improvements in Sexual Relationship and Self-Esteem in Patients with Erectile Dysfunction Treated with Bremelanotide
4. Palatin Technologies and King Pharmaceuticals Announce Plan To Present Results of Bremelanotide Phase 2b Studies in Men With Erectile Dysfunction
5. Genelabs Technologies Announces Presentation of Data on Non-Nucleoside HCV Polymerase Inhibitor at 20th International Conference on Antiviral Research Meeting
6. OncoGenex Technologies Announces Phase II Data of OGX-011 in Metastatic Breast Cancer at American Association for Cancer Research 2007 Annual Meeting
7. AVAX Technologies Presents Results of Phase I-II M-Vax Trial at Annual Meeting of American Association for Cancer Research
8. Emisphere Technologies, Inc. Reports Clinical Data on Oral Delivery of GLP-1 and PYY
9. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
10. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
11. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Micell Technologies Presents Data Novel Drug Eluting Stents
(Date:11/6/2009)... 6 Derma Sciences, Inc...nced wound care products, announced plans to relea... Monday, November 16, 2009. The Company will hold ...ults at 11:00 am EST. Interested parties should ca...ternational), with passcode 81416481 to access the...
(Date:11/6/2009).... 6 Philips Respironics applauds t...Prevention (CDC) to raise awareness about an impor...iency. The CDC,s release of the first-ever governm... sleeplessness is a milestone in quantifying the s...e educator, industry leader and sleep therapy manu...
(Date:11/6/2009)...wswire-FirstCall/ -- Cyberonics, Inc. (Nasdaq: CY...financial results for the second quarter ended Oct...2010 on Wednesday, November 18, 2009 at 5:00 PM ES...discuss those results on Thursday, November 19, 20... Quarter Results Conference Call Instructions ,...
Breaking Medicine Technology:Derma Sciences Announces Date of Its Third Quarter 2009 Earnings Release and Conference Call 2Statement by Don Spence, CEO, Philips Home Healthcare Solutions, Endorsing CDC Educational Initiatives to Raise Awareness of Sleep Deprivation 2Cyberonics Announces Conference Call to Discuss Fiscal Year 2010 Second Quarter Financial Results 2Sedentary Kids May Take Longer to Fall Asleep 52576 1Sedentary Kids May Take Longer to Fall Asleep 52576 2Sedentary Kids May Take Longer to Fall Asleep 52576 3Stripping leukemia initiating cells of their invisibility cloak 52573 1Stripping leukemia initiating cells of their invisibility cloak 52573 2Detecting early signs of osteoarthritis 52570 1Detecting early signs of osteoarthritis 52570 2
...HOVOT Israel, February 12 ,Rosetta Genomics Ltd. (...ivo,efficacy data for a systemic microRNA-based ca...ted a marked suppression of a microRNA that was,fo...carcinoma (HCC), and a,significant two-fold reduct...at the Keystone Symposium, Therapeutic Modulation ...
...surgery hormone therapy reduced risk of breast can...py alone , , - First Phase III data to substantia...e most widely prescribed drug for prevention of bo... than 2.7 million patients treated worldwide , , ...wly published study in The New England Journal of...
Other Medicine Technology:Rosetta Genomics Reports First Ever In-Vivo Efficacy Data for a Systemic MicroRNA Therapeutic for Liver Cancer 2Rosetta Genomics Reports First Ever In-Vivo Efficacy Data for a Systemic MicroRNA Therapeutic for Liver Cancer 3Rosetta Genomics Reports First Ever In-Vivo Efficacy Data for a Systemic MicroRNA Therapeutic for Liver Cancer 4Rosetta Genomics Reports First Ever In-Vivo Efficacy Data for a Systemic MicroRNA Therapeutic for Liver Cancer 5Video: Zometa(R) Reduces Risk of Breast Cancer Recurrence in Premenopausal Women, Study in The New England Journal of Medicine Reports 2Video: Zometa(R) Reduces Risk of Breast Cancer Recurrence in Premenopausal Women, Study in The New England Journal of Medicine Reports 3Video: Zometa(R) Reduces Risk of Breast Cancer Recurrence in Premenopausal Women, Study in The New England Journal of Medicine Reports 4Video: Zometa(R) Reduces Risk of Breast Cancer Recurrence in Premenopausal Women, Study in The New England Journal of Medicine Reports 5Video: Zometa(R) Reduces Risk of Breast Cancer Recurrence in Premenopausal Women, Study in The New England Journal of Medicine Reports 6Video: Zometa(R) Reduces Risk of Breast Cancer Recurrence in Premenopausal Women, Study in The New England Journal of Medicine Reports 7
(Date:11/8/2009)...network of Hispanic health advocates committed to ..., WASHINGTON, Nov. 7 ... they have heard the voice of America,s families b...ct. Now the Senate must deliver, without delay, on...id Dr. Jane L. Delgado, President and CEO of the N...
(Date:11/8/2009)...assage of H.R. 3961 to Secure the Stability of Med...e/ -- Statement Attributable to: J. James Rohack, ..., (Logo: http://www.newscom.com/cgi-bin/prnh/20...e of the House health reform bill, which will help...ians and calls for swift passage of H.R. 3961 to s...
(Date:11/8/2009)...Shows Who Sides With Working Families vs. Insuranc...wire-USNewswire/ -- On the heels of an historic la...a good, balanced health care reform bill, the Penn...tate,s U.S. representatives voted on HR 3962, the ... legislation, which passed Saturday evening by a v...
(Date:11/7/2009)... Karen Ignagni, Preside...IP), released the following statement today on Hou...gly support comprehensive health care reform, and ...g a complete overhaul of how health insurance is p... coverage, elimination of pre-existing condition e...
(Date:11/7/2009)...RNewswire-USNewswire/ -- The American Medical Asso...or of Health at the Family Violence Prevention Fun...ay at its semi-annual policy-making meeting. The ...honor the AMA House of Delegates bestows on a non-...m/cgi-bin/prnh/20081209/AMALOGO ) ,, "Ms. Jam...
Breaking Medicine News(10 mins):Health News:National Alliance for Hispanic Health President and CEO Applauds House Action, Calls on Senate to Pass Health Reform in 2009 2Health News:AMA Hails House Passage of Health Reform Bill (H.R. 3962) 2Health News:Robert Brady (D-PA-1), Chaka Fattah (D-PA-2), Kathy Dahlkemper (D-PA-3), Joe Sestak (D-PA-7), Patrick Murphy (D-PA-8), Christopher Carney (D-PA-10), John Murtha (D-PA-12), Paul Kanjorski (D-PA-11), Allyson Schwartz (D-PA-13), Mike Doyle (D-PA-14) Ge 2Health News:AHIP Statement on House Passage of H.R. 3962 2Health News:AMA Honors Family Violence Prevention Expert 2
... Kids want help from adults,as they face a daunti...res,only scare them away. ethiKids, inc. introduce...pen during the formative pre-teen years., On Dece... related to values and skills development. Its,fir...
...18 - In response to the,press conference introduct...s E. Schumer (D-NY) of a bill -- S 2470, the "Dehy...007 (DARA 2007)," -- which proposes to amend,the C...nsible Nutrition (CRN), the leading trade associat...
...18 Escalon Medical Corp.,(Nasdaq Capital Market: ...sidiary received 510(k) clearance from the U.S. Fo...Hematology System, an automatic,three-part differe...ts a major step for Drew, as it now provides,two u...
...ec. 18 Alsius Corporation,(Nasdaq: ALUS ), which...temperature management therapies, announced today ... all 16,541,000 outstanding, publicly traded,warra...to,receive one share of common stock for every 5.5...
... Dec. 18 Cumberland Pharmaceuticals is,pleased to...., David L. Lowrance has been promoted to Vice Pr... he is responsible for overseeing the,company,s ac...ng Cumberland in 2003 as Director of Finance,and A...
...med President, Labs North America -, PRINCETON, N...nced that Wendel Barr has been named Covance,s Chi...r. Barr, who is currently,President of Early Devel...nd Chief Executive Officer. In addition,Mike Lehma...
Other Medicine News:Health News:ethiKids, inc. Launches Website and Products to Address Declining Ethics in Children 2Health News:Council for Responsible Nutrition Calls Proposed DHEA Legislation 'A Solution in Search of a Problem' 2Health News:Escalon(R) Announces FDA 510(K) Clearance for D3 Hematology System 2Health News:Escalon(R) Announces FDA 510(K) Clearance for D3 Hematology System 3Health News:Alsius Corporation Announces Program for Early Exercise of Warrants 2Health News:Alsius Corporation Announces Program for Early Exercise of Warrants 3Health News:Alsius Corporation Announces Program for Early Exercise of Warrants 4Health News:Cumberland Pharmaceuticals Announces Appointments 2Health News:Wendel Barr Appointed Chief Operating Officer of Covance 2Health News:Wendel Barr Appointed Chief Operating Officer of Covance 3
Distriman
...held manual dispenser, is ideal for process accele...ts increased volume selection provides outstanding...tasks, and its smooth handling reduces the hand fa...mbitips allow a wider range of up to 112 different...
NC Ranger™ Balloon Catheter
... Pacing System Analyzer (PSA Wand), model 3150, of...ng, programming and interrogation of bradycardia a...e accessory to the St. Jude Medical model 3510 pro...ing measurements of intrinsic P- and R-wave signal...
Medicine Products: